An interventional study of Niti-S SPAXUS Stent in Pancreatic Pseudocyst, sponsored by Taewoong Medical Co., Ltd.. Completed at 6 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2019-09-17.
Sponsored by Taewoong Medical Co., Ltd. (part of Olympus Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and effectiveness of endoscopic ultrasound (EUS)-guided transluminal drainage with 'Niti-S SPAXUS Stent' for the treatment of pancreatic pseudocyst.
'Niti-S SPAXUS Stent' is a newly designed lumen-apposing fully covered self-expandable metal stent. It is indicated for use in patients with pancreatic pseudocyst. Consecutive subject data should be collected at discharge, stent removal (day 30 or 60), and day 20 post Niti-S SPAXUS stent removal.
32 studies on the registry are indexed under Pancreatic Pseudocyst; 10 are open to participants now.
This study's enrollment of 36 is below the median of 45 across 21 interventional studies indexed under Pancreatic Pseudocyst.
Browse Pancreatic Pseudocyst studies →Taewoong Medical Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
First submitted before Taewoong Medical Co., Ltd. became part of Olympus Corporation.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)
Device: Niti-S SPAXUS Stent
Endoscopic Ultrasound-Guided Transluminal drainage
Number of Participants With Clinical Success
Clinical success is defined as ≥50% decrease in pancreatic pseudocyst size measured on Computed Tomography (CT)
Time frame: at stent removal (Day 30 or Day 60)
Number of Participants With Technical Success
Technical success is defined as successful placement of the Niti-S SPAXUS stent across the gastric(or duodenal) wall to the pseudocyst with visualization of the pseudocyst fluid drainage through the stent by endoscopy.
Time frame: Day 1
Number of Participants With Stent Lumen Patency
Stent lumen patency will be evaluated by endoscopy.
Time frame: up to 60 days (at stent removal, Day 30 or 60)
Number of Participants With Stent Removal Success
Stent removal success is defined as successful removal of the Niti-S SPAXUS stent using a standard endoscopic forceps or snare.
Time frame: up to 60 days (at stent removal, Day 30 or 60)
Procedure Time
Procedure time is measured as time from insertion until removal of endoscope. Procedure time 1: The time from the moment that the endoscope is inserted into the oral cavity to the time point at which the endoscope is removed. (sec) Procedure time 2: The time from the puncture time to the point at which the ultrasound endoscope was removed. (sec)
Time frame: 1 day
Number of Participants With Procedural/Device Related Serious Adverse Events
The incidence of serious adverse events related to the procedure or the Niti-S SPAXUSTM stent is assessed at Day 20 after the stent removal
Time frame: up to 90 days (at Day 20 post stent removal)
Other Adverse Events
The severity and incidence of all other adverse events than those mentioned above occurred during the follow-up period were evaluated at Day 20 day after the stent removal.
Time frame: up to 90 days (at Day 20 post stent removal)
It took about 15 months from the approval of the Ministry of Food and Drug Safety(MFDS) and the IRB, including the subject enrollment period of about 13 months and the follow-up period of 2 months at maximum.
| Milestone | Niti-S SPAXUS Stent |
|---|---|
| Started | 36 |
| Completed | 35 |
| Not completed | 1 |
Clinical success is defined as ≥50% decrease in pancreatic pseudocyst size measured on Computed Tomography (CT)
| participants | Niti-S SPAXUS Stent |
|---|---|
| Number of Participants With Clinical Success | 33 |
Technical success is defined as successful placement of the Niti-S SPAXUS stent across the gastric(or duodenal) wall to the pseudocyst with visualization of the pseudocyst fluid drainage through the stent by endoscopy.
| Participants | Niti-S SPAXUS Stent |
|---|---|
| Number of Participants With Technical Success | 33 |
Stent lumen patency will be evaluated by endoscopy.
| Participants | Niti-S SPAXUS Stent |
|---|---|
| Number of Participants With Stent Lumen Patency | 34 |
Stent removal success is defined as successful removal of the Niti-S SPAXUS stent using a standard endoscopic forceps or snare.
| Participants | Niti-S SPAXUS Stent |
|---|---|
| Number of Participants With Stent Removal Success | 34 |
Procedure time is measured as time from insertion until removal of endoscope. Procedure time 1: The time from the moment that the endoscope is inserted into the oral cavity to the time point at which the endoscope is removed. (sec) Procedure time 2: The time from the puncture time to the point at which the ultrasound endoscope was removed. (sec)
| sec | Niti-S SPAXUS Stent |
|---|---|
| Procedure time 1 | 1074.88 ± 618.30 |
| Procedure time 2 | 618.12 ± 341.63 |
The incidence of serious adverse events related to the procedure or the Niti-S SPAXUSTM stent is assessed at Day 20 after the stent removal
| participants | Niti-S SPAXUS Stent |
|---|---|
| Number of Participants With Procedural/Device Related Serious Adverse Events | 14 |
The severity and incidence of all other adverse events than those mentioned above occurred during the follow-up period were evaluated at Day 20 day after the stent removal.
| case | Niti-S SPAXUS Stent |
|---|---|
| Other Adverse Events | 154 |
Collected over 3months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Niti-S SPAXUS Stent | 0/35 (0%) | 14/35 (40%) | 29/35 (82.9%) |
| Event | Niti-S SPAXUS Stent |
|---|---|
| Infected pseudocystInfections and infestations | 3/35 |
| Aggravated Walled off necrosisGastrointestinal disorders | 2/35 |
| Abdominal painGastrointestinal disorders | 2/35 |
| Necrotizing pseudocystGastrointestinal disorders | 2/35 |
| Upper gastrointestinal bleedingGastrointestinal disorders | 1/35 |
| DehydrationMetabolism and nutrition disorders | 1/35 |
| Peripancreatic abscessInfections and infestations | 1/35 |
| Pancreatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/35 |
| Abdominal pain (LUQ pain) -> wall-off necrosisGastrointestinal disorders | 1/35 |
| Cerebral infarctionNervous system disorders | 1/35 |
| Event | Niti-S SPAXUS Stent |
|---|---|
| Abdominal pain etc.Gastrointestinal disorders | 24/35 |
| Pyrexia etc.General disorders | 17/35 |
| Decreased appetiteMetabolism and nutrition disorders | 9/35 |
| Pancreas infection etc.Infections and infestations | 7/35 |
| Flank painMusculoskeletal and connective tissue disorders | 6/35 |
| Blood pressure decreasedInvestigations | 5/35 |
| Cholelithiasis etc.Hepatobiliary disorders | 2/35 |
| ThrombocytosisBlood and lymphatic system disorders | 1/35 |
| TachycardiaCardiac disorders | 1/35 |
| Visual impairmentEye disorders | 1/35 |
| Age, Continuous(years) | Niti-S SPAXUS Stent |
|---|---|
| Mean | 52.51 ± 13.22 |
| Sex: Female, Male(Participants) | Niti-S SPAXUS Stent |
|---|---|
| Female | 8 |
| Male | 27 |
| Race and Ethnicity Not Collected(Participants) | Niti-S SPAXUS Stent |
|---|
| Region of Enrollment(participants) | Niti-S SPAXUS Stent |
|---|---|
| South Korea | 35 |
| Height(cm) | Niti-S SPAXUS Stent |
|---|---|
| Mean | 167.82 (144.30 to 182.30) |
| Body weight(kg) | Niti-S SPAXUS Stent |
|---|---|
| Mean | 64.34 (43.50 to 96.00) |
| History of smoking(participants) | Niti-S SPAXUS Stent |
|---|---|
| Current Smoker | 13 |
| Ex-Smoker | 10 |
| Non-Smoker | 12 |
| Alcohol drinking(participants) | Niti-S SPAXUS Stent |
|---|---|
| Current Drinker | 13 |
| Ex-Drinker | 14 |
| Non-Drinker | 8 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Oct, 2016
Ran from Mar 2016 to primary completion in Jun 2017, 14 months.
Results were first posted in Jul 2019, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.